Syneos Health Key Executives
This section highlights Syneos Health's key executives, including their titles and compensation details.
Find Contacts at Syneos Health
(Showing 0 of )
Syneos Health Earnings
This section highlights Syneos Health's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
$42.98
Stock Price
$4.46B
Market Cap
29.39K
Employees
Morrisville, NC
Location
Financial Statements
Access annual & quarterly financial statements for Syneos Health, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Revenue | $5.39B | $5.21B | $4.42B | $4.68B | $4.39B |
| Cost of Revenue | $4.14B | $3.99B | $3.40B | $3.65B | $3.43B |
| Gross Profit | $1.25B | $1.22B | $1.02B | $1.03B | $955.81M |
| Gross Profit Ratio | 23.26% | 23.40% | 23.05% | 22.03% | 21.77% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $406.31M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $547.25M | $570.76M | $442.48M | $446.28M | $406.31M |
| Other Expenses | $247.18M | $235.62M | $222.35M | $242.47M | $28.24M |
| Operating Expenses | $794.43M | $806.39M | $664.84M | $688.75M | $679.99M |
| Cost and Expenses | $4.93B | $4.80B | $4.06B | $4.33B | $4.11B |
| Interest Income | $1.61M | $111.00K | $265.00K | $7.54M | $3.69M |
| Interest Expense | $80.79M | $79.14M | $90.88M | $129.82M | $130.70M |
| Depreciation and Amortization | $296.80M | $267.07M | $284.98M | $242.47M | $273.69M |
| EBITDA | $699.99M | $656.35M | $578.13M | $567.01M | $581.43M |
| EBITDA Ratio | 12.98% | 12.59% | 13.09% | 12.13% | 13.24% |
| Operating Income | $403.19M | $389.28M | $293.14M | $324.54M | $160.18M |
| Operating Income Ratio | 7.48% | 7.47% | 6.64% | 6.94% | 3.65% |
| Total Other Income Expenses Net | $-88.63M | $-74.12M | $-89.48M | $-136.04M | $-102.92M |
| Income Before Tax | $314.56M | $315.16M | $203.66M | $101.71M | $57.26M |
| Income Before Tax Ratio | 5.83% | 6.05% | 4.61% | 2.18% | 1.30% |
| Income Tax Expense | $48.07M | $80.33M | $10.87M | $-29.55M | $32.97M |
| Net Income | $266.50M | $234.83M | $192.79M | $131.26M | $24.28M |
| Net Income Ratio | 4.94% | 4.50% | 4.37% | 2.81% | 0.55% |
| EPS | $2.57 | $2.26 | $1.85 | $1.27 | $0.23 |
| EPS Diluted | $2.54 | $2.24 | $1.83 | $1.25 | $0.23 |
| Weighted Average Shares Outstanding | 102.97M | 103.87M | 104.17M | 103.62M | 103.41M |
| Weighted Average Shares Outstanding Diluted | 103.48M | 105.06M | 105.47M | 105.00M | 104.70M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 | September 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.37B | $1.36B | $1.36B | $1.34B | $1.36B | $1.34B | $1.37B | $1.35B | $1.28B | $1.21B | $1.14B | $1.10B | $1.01B | $1.16B | $1.21B | $1.18B | $1.17B | $1.12B | $1.15B | $1.11B |
| Cost of Revenue | $1.07B | $1.09B | $1.04B | $1.02B | $1.03B | $1.04B | $1.02B | $1.03B | $992.58M | $945.25M | $848.01M | $820.23M | $805.89M | $924.01M | $927.90M | $913.67M | $917.53M | $886.80M | $873.81M | $872.21M |
| Gross Profit | $294.72M | $268.25M | $318.16M | $318.44M | $325.84M | $291.82M | $348.62M | $316.34M | $290.03M | $263.50M | $292.01M | $278.78M | $207.51M | $239.34M | $285.05M | $263.35M | $249.30M | $232.20M | $271.66M | $242.70M |
| Gross Profit Ratio | 21.60% | 19.80% | 23.40% | 23.80% | 23.90% | 21.80% | 25.40% | 23.50% | 22.60% | 21.80% | 25.61% | 25.37% | 20.48% | 20.57% | 23.50% | 22.37% | 21.37% | 20.75% | 23.72% | 21.77% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $182.52M | $161.52M | $137.69M | $130.35M | $139.04M | $140.17M | $149.26M | $139.52M | $144.67M | $137.31M | $108.44M | $111.10M | $104.98M | $117.97M | $112.42M | $109.86M | $110.88M | $113.12M | $109.89M | $96.94M |
| Other Expenses | $-841.00K | $61.59M | $62.24M | $61.51M | $61.22M | $-2.81M | $2.78M | $2.92M | $-1.30M | $1.48M | $403.00K | $-1.10M | $-387.00K | $-1.55M | $-53.53M | $-1.18M | $-614.00K | $-592.00K | $13.14M | $-1.62M |
| Operating Expenses | $241.85M | $223.10M | $199.94M | $191.87M | $200.26M | $202.37M | $212.98M | $195.78M | $202.38M | $195.25M | $163.22M | $166.54M | $161.00M | $174.08M | $172.80M | $170.00M | $171.63M | $174.32M | $180.01M | $164.98M |
| Cost and Expenses | $1.31B | $1.31B | $1.24B | $1.21B | $1.24B | $1.25B | $1.24B | $1.23B | $1.19B | $1.14B | $1.01B | $986.77M | $966.89M | $1.10B | $1.10B | $1.08B | $1.09B | $1.06B | $1.05B | $1.04B |
| Interest Income | $1.71M | $528.00K | $1.27M | $303.00K | $36.00K | $3.00K | $- | $- | $- | $71.00K | $- | $- | $122.00K | $336.00K | $1.48M | $2.43M | $2.13M | $1.50M | $188.00K | $1.00M |
| Interest Expense | $37.88M | $26.26M | $25.13M | $22.13M | $18.10M | $15.77M | $16.49M | $16.77M | $22.62M | $23.33M | $22.75M | $20.44M | $21.68M | $26.46M | $28.32M | $32.61M | $34.26M | $34.63M | $32.97M | $33.10M |
| Depreciation and Amortization | $59.33M | $61.59M | $57.35M | $68.49M | $70.69M | $62.20M | $63.72M | $56.25M | $57.71M | $57.94M | $54.78M | $55.45M | $56.02M | $56.11M | $60.38M | $60.14M | $60.75M | $61.20M | $70.13M | $68.03M |
| EBITDA | $113.06M | $97.37M | $152.20M | $186.33M | $187.29M | $148.85M | $202.14M | $179.74M | $144.06M | $127.73M | $183.97M | $166.58M | $102.27M | $120.16M | $120.59M | $154.74M | $139.94M | $120.00M | $175.11M | $145.15M |
| EBITDA Ratio | 8.28% | 7.18% | 11.19% | 13.94% | 13.76% | 11.14% | 14.72% | 13.33% | 11.23% | 10.57% | 16.14% | 15.16% | 10.09% | 10.33% | 9.94% | 13.15% | 11.99% | 10.72% | 15.29% | 13.02% |
| Operating Income | $42.22M | $35.78M | $94.86M | $117.84M | $116.60M | $73.90M | $131.22M | $113.36M | $83.68M | $61.02M | $110.45M | $98.75M | $34.97M | $48.97M | $83.36M | $69.44M | $58.13M | $26.82M | $79.47M | $39.82M |
| Operating Income Ratio | 3.09% | 2.64% | 6.98% | 8.82% | 8.57% | 5.53% | 9.55% | 8.41% | 6.52% | 5.05% | 9.69% | 8.99% | 3.45% | 4.21% | 6.87% | 5.90% | 4.98% | 2.40% | 6.94% | 3.57% |
| Total Other Income Expenses Net | $-41.56M | $-110.95M | $-54.15M | $-1.16M | $-12.91M | $-20.40M | $-14.52M | $-12.95M | $-32.65M | $-14.00M | $-23.59M | $-31.38M | $-27.32M | $-7.19M | $-65.62M | $532.00K | $-24.56M | $-46.40M | $-19.88M | $-38.23M |
| Income Before Tax | $661.00K | $-75.16M | $40.70M | $116.69M | $103.68M | $53.49M | $116.70M | $100.41M | $51.04M | $47.01M | $86.86M | $67.37M | $7.65M | $41.77M | $17.75M | $69.97M | $33.58M | $-19.59M | $59.59M | $1.59M |
| Income Before Tax Ratio | 0.05% | -5.54% | 2.99% | 8.73% | 7.62% | 4.00% | 8.50% | 7.45% | 3.98% | 3.89% | 7.62% | 6.13% | 0.75% | 3.59% | 1.46% | 5.95% | 2.88% | -1.75% | 5.20% | 0.14% |
| Income Tax Expense | $-132.00K | $-3.01M | $-14.82M | $29.64M | $25.94M | $7.32M | $40.74M | $22.17M | $9.13M | $8.29M | $-5.02M | $3.95M | $3.74M | $8.20M | $-73.31M | $11.05M | $22.29M | $10.42M | $13.92M | $11.98M |
| Net Income | $793.00K | $-72.15M | $55.53M | $87.05M | $77.74M | $46.18M | $75.96M | $78.24M | $41.91M | $38.72M | $91.89M | $63.42M | $3.91M | $33.57M | $91.05M | $58.92M | $11.29M | $-30.00M | $45.67M | $-10.39M |
| Net Income Ratio | 0.06% | -5.32% | 4.08% | 6.51% | 5.71% | 3.46% | 5.53% | 5.80% | 3.27% | 3.20% | 8.06% | 5.77% | 0.39% | 2.89% | 7.51% | 5.01% | 0.97% | -2.68% | 3.99% | -0.93% |
| EPS | $0.01 | $-0.70 | $0.54 | $0.85 | $0.75 | $0.44 | $0.73 | $0.76 | $0.40 | $0.37 | $0.88 | $0.61 | $0.04 | $0.32 | $0.88 | $0.57 | $0.11 | $-0.29 | $0.44 | $-0.10 |
| EPS Diluted | $0.01 | $-0.70 | $0.54 | $0.84 | $0.75 | $0.44 | $0.72 | $0.75 | $0.40 | $0.37 | $0.87 | $0.60 | $0.04 | $0.32 | $0.86 | $0.56 | $0.11 | $-0.29 | $0.44 | $-0.10 |
| Weighted Average Shares Outstanding | 103.68M | 103.33M | 102.91M | 102.73M | 102.60M | 103.67M | 103.72M | 103.56M | 103.94M | 104.27M | 103.93M | 104.28M | 104.20M | 104.27M | 103.81M | 103.59M | 103.70M | 103.36M | 103.30M | 103.01M |
| Weighted Average Shares Outstanding Diluted | 104.34M | 103.33M | 103.22M | 103.21M | 103.07M | 104.41M | 105.00M | 104.78M | 105.02M | 105.46M | 105.41M | 105.59M | 105.22M | 105.64M | 105.38M | 105.02M | 104.82M | 103.36M | 108.44M | 103.01M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $112.00M | $106.47M | $272.17M | $163.69M | $155.93M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $112.00M | $106.47M | $272.17M | $163.69M | $155.93M |
| Net Receivables | $1.65B | $1.52B | $1.34B | $1.30B | $1.26B |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $186.77M | $135.09M | $121.06M | $94.83M | $79.30M |
| Total Current Assets | $1.94B | $1.77B | $1.74B | $1.56B | $1.49B |
| Property Plant Equipment Net | $437.09M | $432.06M | $439.49M | $422.46M | $183.49M |
| Goodwill | $4.90B | $4.96B | $4.78B | $4.35B | $4.33B |
| Intangible Assets | $680.86M | $854.07M | $933.52M | $973.08M | $1.13B |
| Goodwill and Intangible Assets | $5.58B | $5.81B | $5.71B | $5.32B | $5.47B |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $50.68M | $35.39M | $35.06M | $37.01M | $9.32M |
| Other Non-Current Assets | $189.13M | $193.10M | $141.05M | $108.70M | $103.37M |
| Total Non-Current Assets | $6.26B | $6.47B | $6.33B | $5.89B | $5.76B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $8.20B | $8.24B | $8.06B | $7.45B | $7.25B |
| Account Payables | $118.62M | $107.53M | $113.68M | $136.69M | $98.62M |
| Short Term Debt | $68.00M | $63.69M | $59.54M | $113.96M | $63.91M |
| Tax Payables | $22.69M | $25.72M | $28.89M | $17.30M | $30.76M |
| Deferred Revenue | $923.88M | $868.46M | $793.07M | $696.91M | $777.14M |
| Other Current Liabilities | $591.51M | $588.72M | $582.15M | $551.62M | $532.77M |
| Total Current Liabilities | $1.72B | $1.65B | $1.58B | $1.52B | $1.50B |
| Long Term Debt | $2.83B | $3.02B | $3.16B | $2.81B | $2.76B |
| Deferred Revenue Non-Current | $92.16M | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $92.16M | $78.06M | $20.22M | $11.10M | $25.12M |
| Other Non-Current Liabilities | $-35.64M | $76.66M | $68.31M | $90.93M | $106.67M |
| Total Non-Current Liabilities | $2.98B | $3.17B | $3.24B | $2.91B | $2.90B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $4.70B | $4.82B | $4.82B | $4.42B | $4.40B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $1.03M | $1.04M | $1.04M | $1.04M | $1.03M |
| Retained Earnings | $167.69M | $-12.95M | $-179.87M | $-341.26M | $-459.33M |
| Accumulated Other Comprehensive Income Loss | $-133.87M | $-49.62M | $-40.80M | $-71.59M | $-88.19M |
| Other Total Stockholders Equity | $3.46B | $3.47B | $3.46B | $3.44B | $3.40B |
| Total Stockholders Equity | $3.50B | $3.41B | $3.24B | $3.03B | $2.86B |
| Total Equity | $3.50B | $3.41B | $3.24B | $3.03B | $2.86B |
| Total Liabilities and Stockholders Equity | $8.20B | $8.24B | $8.06B | $7.45B | $7.25B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $8.20B | $8.24B | $8.06B | $7.45B | $7.25B |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $2.90B | $3.08B | $3.21B | $2.92B | $2.83B |
| Net Debt | $2.79B | $2.97B | $2.94B | $2.76B | $2.67B |
Balance Sheet Charts
| Breakdown | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 | September 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $82.17M | $111.06M | $112.00M | $170.00M | $105.88M | $119.04M | $106.47M | $122.42M | $260.87M | $264.69M | $272.17M | $248.90M | $343.03M | $335.96M | $163.69M | $129.20M | $107.26M | $107.92M | $155.93M | $132.40M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $82.17M | $111.06M | $112.00M | $170.00M | $105.88M | $119.04M | $106.47M | $122.42M | $260.87M | $264.69M | $272.17M | $248.90M | $343.03M | $335.96M | $163.69M | $129.20M | $107.26M | $107.92M | $155.93M | $132.40M |
| Net Receivables | $1.70B | $1.65B | $1.65B | $1.65B | $1.61B | $1.60B | $1.52B | $1.53B | $1.37B | $1.30B | $1.34B | $1.26B | $1.17B | $1.34B | $1.30B | $1.30B | $1.29B | $1.22B | $1.26B | $1.14B |
| Inventory | $109.00K | $- | $- | $105.00K | $108.00K | $111.00K | $- | $110.00K | $267.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.20M |
| Other Current Assets | $169.95M | $184.32M | $186.77M | $145.65M | $168.93M | $160.79M | $135.09M | $114.63M | $117.24M | $110.52M | $121.06M | $82.31M | $80.35M | $- | $94.83M | $68.22M | $71.98M | $78.18M | $79.30M | $80.42M |
| Total Current Assets | $1.95B | $1.95B | $1.94B | $1.96B | $1.88B | $1.88B | $1.77B | $1.76B | $1.75B | $1.67B | $1.74B | $1.60B | $1.60B | $1.77B | $1.56B | $1.49B | $1.47B | $1.41B | $1.49B | $1.36B |
| Property Plant Equipment Net | $332.65M | $356.62M | $437.09M | $441.48M | $439.92M | $441.42M | $432.06M | $426.58M | $426.02M | $417.67M | $439.49M | $409.31M | $408.37M | $414.06M | $422.46M | $421.47M | $415.46M | $415.38M | $183.49M | $175.13M |
| Goodwill | $4.91B | $4.91B | $4.90B | $4.85B | $4.90B | $4.94B | $4.96B | $4.90B | $4.79B | $4.78B | $4.78B | $4.34B | $4.32B | $4.32B | $4.35B | $4.32B | $4.34B | $4.34B | $4.33B | $4.35B |
| Intangible Assets | $608.43M | $644.84M | $680.86M | $710.64M | $759.44M | $808.93M | $854.07M | $880.85M | $831.07M | $896.39M | $933.52M | $882.49M | $913.38M | $925.39M | $973.08M | $1.00B | $1.05B | $1.10B | $1.13B | $1.19B |
| Goodwill and Intangible Assets | $5.52B | $5.55B | $5.58B | $5.56B | $5.66B | $5.75B | $5.81B | $5.78B | $5.62B | $5.68B | $5.71B | $5.23B | $5.24B | $5.25B | $5.32B | $5.33B | $5.39B | $5.44B | $5.47B | $5.54B |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $57.63M | $48.18M | $50.68M | $30.62M | $33.67M | $34.79M | $35.39M | $39.03M | $37.61M | $34.96M | $35.06M | $18.26M | $34.31M | $34.24M | $37.01M | $5.50M | $9.11M | $9.15M | $9.32M | $32.70M |
| Other Non-Current Assets | $213.32M | $195.78M | $189.13M | $201.38M | $203.72M | $199.84M | $193.10M | $209.39M | $186.89M | $151.08M | $141.05M | $135.61M | $130.45M | $118.63M | $108.70M | $131.07M | $118.24M | $113.87M | $103.37M | $102.95M |
| Total Non-Current Assets | $6.12B | $6.15B | $6.26B | $6.23B | $6.33B | $6.43B | $6.47B | $6.45B | $6.27B | $6.28B | $6.33B | $5.79B | $5.81B | $5.82B | $5.89B | $5.88B | $5.93B | $5.98B | $5.76B | $5.85B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $8.08B | $8.10B | $8.20B | $8.20B | $8.22B | $8.30B | $8.24B | $8.22B | $8.02B | $7.95B | $8.06B | $7.38B | $7.41B | $7.59B | $7.45B | $7.38B | $7.40B | $7.39B | $7.25B | $7.21B |
| Account Payables | $137.02M | $145.97M | $118.62M | $118.95M | $99.32M | $108.31M | $107.53M | $110.35M | $107.77M | $113.88M | $113.68M | $104.94M | $92.49M | $112.31M | $136.69M | $82.84M | $128.81M | $94.28M | $98.62M | $82.20M |
| Short Term Debt | $68.27M | $64.46M | $68.00M | $66.18M | $64.09M | $65.23M | $63.69M | $64.42M | $60.70M | $57.62M | $59.54M | $113.13M | $143.90M | $134.67M | $113.96M | $77.08M | $245.34M | $40.60M | $63.91M | $78.65M |
| Tax Payables | $- | $- | $22.69M | $- | $- | $- | $25.72M | $- | $- | $- | $28.89M | $- | $- | $- | $17.30M | $- | $- | $- | $30.76M | $- |
| Deferred Revenue | $803.92M | $859.38M | $923.88M | $885.01M | $887.18M | $891.75M | $868.46M | $819.90M | $802.26M | $773.02M | $793.07M | $710.17M | $657.98M | $689.67M | $696.91M | $703.92M | $710.90M | $713.31M | $777.14M | $709.03M |
| Other Current Liabilities | $617.95M | $618.09M | $591.51M | $653.20M | $656.87M | $657.08M | $588.72M | $693.60M | $625.62M | $587.76M | $582.15M | $583.01M | $532.36M | $504.35M | $551.62M | $587.89M | $569.45M | $535.52M | $532.77M | $527.23M |
| Total Current Liabilities | $1.63B | $1.69B | $1.72B | $1.72B | $1.71B | $1.72B | $1.65B | $1.69B | $1.60B | $1.53B | $1.58B | $1.51B | $1.43B | $1.44B | $1.52B | $1.45B | $1.65B | $1.38B | $1.50B | $1.40B |
| Long Term Debt | $2.83B | $2.82B | $2.83B | $2.98B | $3.04B | $3.14B | $3.02B | $3.14B | $3.11B | $3.10B | $3.16B | $2.70B | $2.88B | $3.07B | $2.81B | $2.94B | $2.79B | $3.05B | $2.76B | $2.80B |
| Deferred Revenue Non-Current | $- | $- | $92.16M | $82.28M | $82.52M | $- | $- | $- | $- | $- | $- | $- | $8.15M | $9.90M | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $69.33M | $74.90M | $92.16M | $82.28M | $82.52M | $78.61M | $78.06M | $7.53M | $13.74M | $17.04M | $20.22M | $7.93M | $9.51M | $8.99M | $11.10M | $33.50M | $33.22M | $26.82M | $25.12M | $58.61M |
| Other Non-Current Liabilities | $58.18M | $65.95M | $-35.64M | $-27.29M | $-28.10M | $59.42M | $76.66M | $61.30M | $64.13M | $64.44M | $68.31M | $65.60M | $74.14M | $73.30M | $90.93M | $85.58M | $93.42M | $88.92M | $106.67M | $123.75M |
| Total Non-Current Liabilities | $2.95B | $2.96B | $2.98B | $3.12B | $3.18B | $3.28B | $3.17B | $3.21B | $3.18B | $3.19B | $3.24B | $2.78B | $2.98B | $3.17B | $2.91B | $3.06B | $2.92B | $3.17B | $2.90B | $2.98B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $4.58B | $4.64B | $4.70B | $4.84B | $4.89B | $5.00B | $4.82B | $4.90B | $4.78B | $4.72B | $4.82B | $4.29B | $4.41B | $4.61B | $4.42B | $4.51B | $4.57B | $4.55B | $4.40B | $4.38B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $1.04M | $1.04M | $1.03M | $1.03M | $1.03M | $1.03M | $1.04M | $1.04M | $1.03M | $1.04M | $1.04M | $1.04M | $1.04M | $1.04M | $1.04M | $1.04M | $1.03M | $1.04M | $1.03M | $1.03M |
| Retained Earnings | $96.34M | $95.55M | $167.69M | $112.17M | $25.12M | $-52.63M | $-12.95M | $-88.91M | $-167.16M | $-165.83M | $-179.87M | $-268.62M | $-318.84M | $-322.75M | $-341.26M | $-432.31M | $-488.84M | $-493.81M | $-459.33M | $-505.00M |
| Accumulated Other Comprehensive Income Loss | $-105.62M | $-124.72M | $-133.87M | $-208.53M | $-122.66M | $-57.36M | $-49.62M | $-48.39M | $-25.64M | $-39.17M | $-40.80M | $-90.32M | $-129.37M | $-131.11M | $-71.59M | $-127.03M | $-92.69M | $-71.81M | $-88.19M | $-53.73M |
| Other Total Stockholders Equity | $3.50B | $3.48B | $3.46B | $3.45B | $3.43B | $3.41B | $3.47B | $3.46B | $3.43B | $3.44B | $3.46B | $3.45B | $3.45B | $3.43B | $3.44B | $3.43B | $3.40B | $3.40B | $3.40B | $3.39B |
| Total Stockholders Equity | $3.49B | $3.45B | $3.50B | $3.35B | $3.33B | $3.30B | $3.41B | $3.32B | $3.24B | $3.24B | $3.24B | $3.10B | $3.00B | $2.98B | $3.03B | $2.87B | $2.82B | $2.84B | $2.86B | $2.83B |
| Total Equity | $3.49B | $3.45B | $3.50B | $3.35B | $3.33B | $3.30B | $3.41B | $3.32B | $3.24B | $3.24B | $3.24B | $3.10B | $3.00B | $2.98B | $3.03B | $2.87B | $2.82B | $2.84B | $2.86B | $2.83B |
| Total Liabilities and Stockholders Equity | $8.08B | $8.10B | $8.20B | $8.20B | $8.22B | $8.30B | $8.24B | $8.22B | $8.02B | $7.95B | $8.06B | $7.38B | $7.41B | $7.59B | $7.45B | $7.38B | $7.40B | $7.39B | $7.25B | $7.21B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $8.08B | $8.10B | $8.20B | $8.20B | $8.22B | $8.30B | $8.24B | $8.22B | $8.02B | $7.95B | $8.06B | $7.38B | $7.41B | $7.59B | $7.45B | $7.38B | $7.40B | $7.39B | $7.25B | $7.21B |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $2.90B | $2.88B | $2.90B | $3.05B | $3.11B | $3.21B | $3.08B | $3.20B | $3.17B | $3.16B | $3.21B | $2.82B | $3.03B | $3.21B | $2.92B | $3.02B | $3.04B | $3.09B | $2.83B | $2.88B |
| Net Debt | $2.81B | $2.77B | $2.79B | $2.88B | $3.00B | $3.09B | $2.97B | $3.08B | $2.91B | $2.90B | $2.94B | $2.57B | $2.69B | $2.88B | $2.76B | $2.89B | $2.93B | $2.98B | $2.67B | $2.74B |
Annual Cash Flow
| Breakdown | March 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $- | $266.50M | $234.83M | $192.79M | $131.26M |
| Depreciation and Amortization | $- | $247.18M | $235.62M | $222.35M | $242.47M |
| Deferred Income Tax | $- | $-1.86M | $46.52M | $-3.84M | $-40.07M |
| Stock Based Compensation | $- | $57.27M | $65.20M | $58.49M | $55.19M |
| Change in Working Capital | $- | $-126.72M | $-137.15M | $-41.69M | $-93.06M |
| Accounts Receivables | $- | $-88.25M | $-109.36M | $16.32M | $-120.39M |
| Inventory | $- | $- | $-24.62M | $2.56M | $-28.32M |
| Accounts Payables | $- | $20.93M | $24.62M | $-2.56M | $28.32M |
| Other Working Capital | $- | $-59.39M | $-27.78M | $-58.01M | $27.33M |
| Other Non Cash Items | $- | $-15.38M | $5.24M | $-2.61M | $22.69M |
| Net Cash Provided by Operating Activities | $- | $426.98M | $450.28M | $425.49M | $318.48M |
| Investments in Property Plant and Equipment | $- | $-93.46M | $-56.84M | $-50.01M | $-63.97M |
| Acquisitions Net | $- | $-12.18M | $-284.66M | $-454.07M | $-17.69M |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-7.69M | $1.16M | $2.38M | $-16.98M |
| Net Cash Used for Investing Activities | $- | $-105.63M | $-340.35M | $-504.08M | $-81.66M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $23.70M | $- | $- | $- |
| Common Stock Repurchased | $- | $-149.96M | $-117.52M | $-70.15M | $-56.72M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $-339.16M | $-277.58M | $178.26M | $-215.47M |
| Net Cash Used Provided by Financing Activities | $- | $-339.16M | $-277.58M | $178.26M | $-215.47M |
| Effect of Forex Changes on Cash | $- | $23.34M | $1.95M | $8.81M | $-13.59M |
| Net Change in Cash | $- | $5.53M | $-165.70M | $108.48M | $7.76M |
| Cash at End of Period | $- | $112.00M | $106.47M | $272.17M | $163.69M |
| Cash at Beginning of Period | $- | $106.47M | $272.17M | $163.69M | $155.93M |
| Operating Cash Flow | $- | $426.98M | $450.28M | $425.49M | $318.48M |
| Capital Expenditure | $- | $-93.46M | $-56.84M | $-50.01M | $-63.97M |
| Free Cash Flow | $- | $333.52M | $393.44M | $375.48M | $254.51M |
Cash Flow Charts
| Breakdown | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 | September 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $793.00K | $-72.15M | $55.53M | $87.05M | $77.74M | $46.18M | $75.96M | $78.24M | $41.91M | $38.72M | $91.89M | $63.42M | $3.91M | $33.57M | $91.05M | $58.92M | $11.29M | $-30.00M | $45.67M | $-10.39M |
| Depreciation and Amortization | $59.33M | $61.59M | $62.24M | $61.51M | $61.22M | $62.20M | $63.72M | $56.25M | $57.71M | $57.94M | $54.78M | $55.45M | $56.02M | $56.11M | $60.38M | $60.14M | $60.75M | $61.20M | $70.13M | $68.03M |
| Deferred Income Tax | $-18.58M | $-12.05M | $-10.66M | $4.59M | $3.21M | $1.00M | $67.85M | $-8.30M | $-8.37M | $-4.65M | $-25.14M | $12.56M | $591.00K | $8.16M | $-53.16M | $4.30M | $7.25M | $1.54M | $961.00K | $6.96M |
| Stock Based Compensation | $20.13M | $18.69M | $10.77M | $12.97M | $16.19M | $17.33M | $16.31M | $15.10M | $16.44M | $17.35M | $11.22M | $15.09M | $16.18M | $16.00M | $14.33M | $12.80M | $13.79M | $14.27M | $8.28M | $9.79M |
| Change in Working Capital | $-106.61M | $11.33M | $-17.10M | $-10.47M | $-44.95M | $-54.20M | $-40.51M | $-92.21M | $-30.90M | $26.48M | $-23.76M | $2.84M | $113.94M | $-134.71M | $25.07M | $-57.17M | $5.01M | $-65.97M | $5.04M | $46.32M |
| Accounts Receivables | $-107.26M | $-66.86M | $-10.65M | $- | $-27.70M | $-49.91M | $44.80M | $-145.89M | $-39.27M | $31.00M | $774.00K | $-37.13M | $105.75M | $-53.08M | $-10.31M | $-20.55M | $-64.06M | $-25.47M | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $33.83M | $-18.72M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $652.00K | $44.36M | $12.28M | $-10.47M | $-17.25M | $-4.30M | $-85.31M | $53.68M | $8.36M | $-4.52M | $-24.54M | $39.97M | $8.19M | $-81.63M | $35.38M | $-36.62M | $69.07M | $-40.50M | $5.04M | $46.32M |
| Other Non Cash Items | $11.24M | $23.02M | $23.03M | $-23.29M | $-13.51M | $-1.62M | $2.65M | $-583.00K | $11.93M | $-8.75M | $5.35M | $6.65M | $3.13M | $-17.74M | $22.88M | $-4.57M | $-1.27M | $5.66M | $-17.62M | $5.12M |
| Net Cash Provided by Operating Activities | $-33.68M | $30.42M | $123.82M | $132.38M | $99.90M | $70.89M | $185.98M | $48.50M | $88.71M | $127.09M | $114.33M | $156.00M | $193.77M | $-38.61M | $160.55M | $74.42M | $96.82M | $-13.31M | $112.45M | $125.83M |
| Investments in Property Plant and Equipment | $-17.96M | $-27.51M | $-23.63M | $-21.92M | $-24.44M | $-23.47M | $-26.92M | $-7.58M | $-11.16M | $-11.17M | $-11.52M | $-8.41M | $-18.21M | $-11.87M | $-13.33M | $-22.58M | $-16.62M | $-11.45M | $-11.63M | $-10.38M |
| Acquisitions Net | $-943.00K | $-113.00K | $-2.46M | $-6.56M | $-1.13M | $-2.02M | $-53.24M | $-217.48M | $-5.33M | $-8.61M | $-447.21M | $343.00K | $-452.00K | $-6.75M | $-8.46M | $-6.23M | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $- | $-3.84M | $5.00M | $- | $- | $- | $- | $- | $- | $- | $-3.00M | $- | $- | $-90.89M |
| Net Cash Used for Investing Activities | $-18.91M | $-27.62M | $-26.09M | $-28.48M | $-25.57M | $-25.50M | $-80.16M | $-228.90M | $-11.50M | $-19.78M | $-458.73M | $-8.07M | $-18.66M | $-18.62M | $-21.79M | $-28.81M | $-19.62M | $-11.45M | $-11.63M | $-101.27M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $11.96M | $23.70M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $-149.96M | $- | $- | $-73.02M | $-44.51M | $-8.12M | $-30.00M | $- | $-32.03M | $- | $-7.04M | $-23.05M | $-26.62M | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $48.71M | $199.00K | $-149.67M | $-54.97M | $-97.95M | $-36.57M | $-122.09M | $35.34M | $-79.46M | $-111.37M | $366.44M | $-244.41M | $-173.68M | $229.92M | $-91.58M | $-23.97M | $-73.58M | $-26.34M | $-72.68M | $-66.98M |
| Net Cash Used Provided by Financing Activities | $25.95M | $199.00K | $-149.67M | $-54.97M | $-97.95M | $-36.57M | $-122.09M | $35.34M | $-79.46M | $-111.37M | $366.44M | $-244.41M | $-173.68M | $229.92M | $-91.58M | $-23.97M | $-73.58M | $-26.34M | $-72.68M | $-66.98M |
| Effect of Forex Changes on Cash | $-2.14M | $-3.95M | $-6.16M | $15.19M | $10.45M | $3.86M | $219.00K | $6.46M | $-1.30M | $-3.42M | $1.24M | $2.35M | $5.64M | $-420.00K | $-12.69M | $305.00K | $-4.29M | $3.08M | $-6.81M | $3.31M |
| Net Change in Cash | $-28.78M | $-949.00K | $-58.10M | $64.11M | $-13.16M | $12.68M | $-16.06M | $-138.60M | $-3.55M | $-7.48M | $23.28M | $-94.13M | $7.07M | $172.27M | $34.48M | $21.95M | $-665.00K | $-48.01M | $21.33M | $-39.12M |
| Cash at End of Period | $82.28M | $111.06M | $112.00M | $170.10M | $105.99M | $119.15M | $106.47M | $122.53M | $261.13M | $264.69M | $272.17M | $248.90M | $343.03M | $335.96M | $163.69M | $129.20M | $107.26M | $107.92M | $155.93M | $134.60M |
| Cash at Beginning of Period | $111.06M | $112.00M | $170.10M | $105.99M | $119.15M | $106.47M | $122.53M | $261.13M | $264.69M | $272.17M | $248.90M | $343.03M | $335.96M | $163.69M | $129.20M | $107.26M | $107.92M | $155.93M | $134.60M | $173.72M |
| Operating Cash Flow | $-33.68M | $30.42M | $123.82M | $132.38M | $99.90M | $70.89M | $185.98M | $48.50M | $88.71M | $127.09M | $114.33M | $156.00M | $193.77M | $-38.61M | $160.55M | $74.42M | $96.82M | $-13.31M | $112.45M | $125.83M |
| Capital Expenditure | $-17.96M | $-27.51M | $-23.63M | $-21.92M | $-24.44M | $-23.47M | $-26.92M | $-7.58M | $-11.16M | $-11.17M | $-11.52M | $-8.41M | $-18.21M | $-11.87M | $-13.33M | $-22.58M | $-16.62M | $-11.45M | $-11.63M | $-10.38M |
| Free Cash Flow | $-51.64M | $2.92M | $100.19M | $110.45M | $75.46M | $47.41M | $159.06M | $40.92M | $77.54M | $115.92M | $102.81M | $147.59M | $175.56M | $-50.48M | $147.22M | $51.84M | $80.20M | $-24.75M | $100.82M | $115.45M |
Syneos Health Dividends
Explore Syneos Health's dividend history, including dividend yield, payout ratio, and historical payments.
Syneos Health News
Read the latest news about Syneos Health, including recent articles, headlines, and updates.
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization
TAMPA, FL, March 25, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce Michele Rath as Senior Vice President and Chief Commercial Officer (CCO) of Scienture, LLC, a wholly owned subsidiary of the Company, leading and managing Scienture, LLC's commercial operations. Under Ms. Rath's leadership, Scienture, LLC has formalized a strategic relationship with Syneos Health Commercial Services, LLC (“Syneos Health”), a premier biopharmaceutical solutions organization, by executing a Master Commercial Services Agreement with Syneos Health (the “MCSA”). Pursuant to the MCSA, Syneos Health will serve as Scienture, LLC's Contract Sales Organization (CSO). This collaboration is set to enhance Scienture, LLC's commercial capabilities and expand its market reach through Syneos Health's proven expertise in outsourced sales solutions.
Syneos Health Appoints Costa Panagos as Chief Executive Officer
Colin Shannon Appointed Executive Chairman Seasoned Executive Further Strengthens Company's Leadership Team MORRISVILLE, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of Costa Panagos as CEO and a member of the Company's Board of Directors, effective immediately.
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE ® Crossject expanding market access activities in preparation for filing for marketing authorization ZEPIZURE®, previously known as ZENEO® Midazolam, is separately contracted with BARDA for U.S. advanced regulatory development and specific supply to the Strategic National Stockpile Dijon, France, January 4, 2024, 18:00 CET -- Crossject (ISIN: FR0011716265; uronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, has engaged Syneos Health, a leading fully integrated biopharmaceutical solutions organization, to prepare for the commercial launch of Crossject's ZEPIZURE® innovative rescue therapy for epileptic seizures in the U.S. Under the agreement, Syneos Health will provide support in all pre-launch and launch activities for ZEPIZURE®. Syneos Health brings a strong U.S. presence and significant expertise in commercializing new therapies for Crossject.
Syneos Health Closes Transaction with Private Investment Firms
Transaction Will Drive Ongoing Transformation and Accelerate Delivery of Tech-Enabled, Fit-for-Purpose Solutions to Biopharma Customers Transaction Will Drive Ongoing Transformation and Accelerate Delivery of Tech-Enabled, Fit-for-Purpose Solutions to Biopharma Customers
Civitas Resources Set to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600
NEW YORK , Sept. 26, 2023 /PRNewswire/ -- S&P SmallCap 600 constituent Civitas Resources Inc. (NYSE: CIVI) will replace Syneos Health Inc. (NASD: SYNH) in the S&P MidCap 400, and Hayward Holdings Inc. (NYSE: HAYW) will replace Civitas Resources in the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 29.
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Syneos Health, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 25, 2023 - (NASDAQ: SYNH)
NEW YORK , Sept. 26, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Syneos Health, Inc..
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Syneos Health, Inc. ("Syneos" or "the Company") (NASDAQ:SYNH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 9, 2020 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Syneos Health, Inc. ("Syneos" or "the Company") (NASDAQ: SYNH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 9, 2020 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Syneos Health, Inc. (SYNH)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 25, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Syneos Health, Inc. (“Syneos” or the “Company”) (NASDAQ: SYNH) common stock between September 9, 2020 and November 3, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On February 17, 2022, Syneos disclosed that its rei.
Attention SYNH Shareholders: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed against Syneos Health, Inc. (SYNH) and Encourages Investors to Contact the Firm
RADNOR, Pa. , Sept. 22, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been against Syneos Health, Inc. ("Syneos") (NASDAQ: SYNH).
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Syneos Health, Inc. ("Syneos" or "the Company") (NASDAQ:SYNH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 9, 2020 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Syneos Health, Inc.(SYNH) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Syneos Health, Inc. ("Syneos" or the "Company") (NASDAQ: SYNH) of a class action securities lawsuit.
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Syneos Health, Inc. Investors to Secure Counsel Before Important September 25 Deadline in Securities Class Action - SYNH
NEW YORK , Sept. 18, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Syneos Health, Inc. (NASDAQ: SYNH) between September 9, 2020 and November 3, 2022, both dates inclusive (the "Class Period"), of the important September 25, 2023 lead plaintiff deadline.
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Syneos Investors of a Lead Plaintiff Deadline of September 25, 2023
NEW YORK , Sept. 18, 2023 /PRNewswire/ -- Attention Syneos Health, Inc. ("Syneos") (NASDAQ: SYNH) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between September 9, 2020 and November 3, 2022.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Syneos Health, Inc. ("Syneos" or "the Company") (NASDAQ: SYNH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 9, 2020 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.
Final Deadline Approaching for Syneos Health, Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Syneos Health, Inc. (SYNH) Investors of September 25, 2023 Lead Plaintiff Deadline
RADNOR, Pa.--(BUSINESS WIRE)---- $SYNH #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Syneos Health, Inc. (“Syneos”) (NASDAQ: SYNH). The action charges Syneos with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Syneos's materially misleading statements and omissions to the pub.
Syneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health Equity
MORRISVILLE, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic collaboration that will expand its relationship with Oracle. Using the Oracle Cerner Learning Health Network (LHN) and elements of Oracle's suite of study startup solutions, the companies seek to help reduce the time it takes to recruit patients for clinical studies and increase the diversity of patient populations participating in medical research.
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Syneos Health, Inc. ("Syneos" or "the Company") (NASDAQ:SYNH) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 9, 2020 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for SYNH.